News articles about Aethlon Medical (OTCMKTS:AEMD) have been trending very positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aethlon Medical earned a media sentiment score of 0.51 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the next few days.

Insider Buying and Selling by Quarter for Aethlon Medical (OTCMKTS:AEMD)

Aethlon Medical (AEMD) traded down 8.58% during midday trading on Friday, hitting $2.13. The stock had a trading volume of 35,828 shares. The firm’s market capitalization is $16.96 million. Aethlon Medical has a 1-year low of $1.53 and a 1-year high of $9.09. The firm has a 50-day moving average price of $2.00 and a 200-day moving average price of $3.26.

COPYRIGHT VIOLATION WARNING: “Aethlon Medical (AEMD) Given News Impact Rating of 0.51” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at

About Aethlon Medical

Aethlon Medical, Inc is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities.

Receive News & Stock Ratings for Aethlon Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical Inc. and related stocks with our FREE daily email newsletter.